Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AC Immune SA (ACIU)
NASDAQ:ACIU
Holding ACIU?
Track your performance easily
ACIU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $5.14
Previous Close$3.38
Volume63.26K
Average Volume (3M)102.64K
Market Cap
$336.92M
Enterprise Value$251.95M
Total Cash (Recent Filing)CHF78.49M
Total Debt (Recent Filing)CHF3.50M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 25, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding99,197,829
10 Day Avg. Volume183,919
30 Day Avg. Volume102,644
Standard Deviation0.21
R-Squared0.10
Alpha-0.00711
Financial Highlights & Ratios
Price to Book (P/B)2.00
Price to Sales (P/S)18.52
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside255.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
AC Immune SA News
PremiumCompany Announcements
AC Immune Q3 2024: Strong Progress and Financial Turnaround
PremiumCompany Announcements
AC Immune’s Promising Trial Results for Parkinson’s Therapy
PremiumCompany Announcements
AC Immune SA Reports Profitable Q3 2024 Results
PremiumCompany Announcements
AC Immune SA Welcomes New CMO Dr. Anke Post
PremiumCompany Announcements
AC Immune Advances in Alzheimer’s Trial, Secures Funding
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company ended with ~CHF 175M in cash, which along with the anticipated ~CHF 25M milestone payment from J&J for ACI-35.030 should provide a 3-year cash runway.
Pipeline And ResearchThe company announced a novel morADC platform with preclinical data highlighting its enhanced targeted interventions and potential simultaneous combination approaches.
Strategic PartnershipsThe recent deal with Takeda for this program likely turned some heads and will likely result in much more aggressive development timelines if early data are encouraging.
Bears Say
Investment RiskThe anti-Tau approach is seen as a higher risk as the exact domains of Tau aggregates that drive toxicity are still being determined.
Research And DevelopmentThe anti-Tau approach is seen as higher risk as the exact domains of Tau aggregates that drive toxicity are still being determined.
Scientific UncertaintyThe anti-Tau approach is seen as a higher risk as the exact domains of Tau aggregates that drive toxicity are still being determined.
---
Ownership Overview
―
Insiders
1.21% Mutual Funds
22.70% Other Institutional Investors
75.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACIU FAQ
What was AC Immune SA’s price range in the past 12 months?
AC Immune SA lowest stock price was $2.25 and its highest was $5.14 in the past 12 months.
What is AC Immune SA’s market cap?
Currently, no data Available
When is AC Immune SA’s upcoming earnings report date?
AC Immune SA’s upcoming earnings report date is Mar 25, 2025 which is in 120 days.
How were AC Immune SA’s earnings last quarter?
AC Immune SA released its earnings results on Nov 05, 2024. The company reported $0.057 earnings per share for the quarter, beating the consensus estimate of -$0.155 by $0.212.
Is AC Immune SA overvalued?
According to Wall Street analysts AC Immune SA’s price is currently Undervalued.
Does AC Immune SA pay dividends?
AC Immune SA does not currently pay dividends.
What is AC Immune SA’s EPS estimate?
AC Immune SA’s EPS estimate is -$0.21.
How many shares outstanding does AC Immune SA have?
AC Immune SA has 99,680,405 shares outstanding.
What happened to AC Immune SA’s price movement after its last earnings report?
AC Immune SA reported an EPS of $0.057 in its last earnings report, beating expectations of -$0.155. Following the earnings report the stock price went up 10.204%.
Which hedge fund is a major shareholder of AC Immune SA?
Among the largest hedge funds holding AC Immune SA’s share is Platinum Investment Management. It holds AC Immune SA’s shares valued at 4M.
---
AC Immune SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (255.03% Upside)
$12.00 (255.03% Upside)
Blogger Sentiment
Bullish
ACIU Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.55%
12-Months-Change
Fundamentals
Return on Equity
-30.57%
Trailing 12-Months
Asset Growth
85.25%
Trailing 12-Months
Company Description
AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
---
ACIU Stock 12 Month Forecast
Average Price Target
$12.00
▲(255.03% Upside)
Technical Analysis
Best Analysts Covering ACIU
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+13.71%
reiterated a buy rating 10 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +13.71% per trade.
---